Germany-based synthetic biology startup Cambrium secures €8M in seed funding. This round was led by Essential Capital, along with SNR, Valor Equity Partners, and HOF Capital.
The company intends to use the funds to scale up its manufacturing and commercial operations so that NovaCollTM can entirely substitute conventional collagen extracted from animals, translating the product’s early triumphs into long-lasting effects.
Additionally, the money will speed up the company’s product pipeline, resulting in the launch of molecules for new industries and applications within the next two years.
Under the leadership of CEO Mitchell Duffy, Cambrium creates, scales, and produces innovative molecular building blocks for uses in fashion, personal hygiene, and other fields.
Converging advances in artificial intelligence, automation, and synthetic biology enable its platform, enabling the creation of novel biomolecules for the aforementioned consumer applications.
Cambrium’s goal is to use the molecular building blocks of biology to spark the next generation of material innovation. They firmly think that the most significant manufacturing technology of the twenty-first century is biology, because it can combine environmental and economic incentives.
They develop new material building blocks with previously unattainable functionality using their molecular design technology. Their molecules give entrepreneurs the ability to produce goods that benefit both people and the environment.
Their mission to develop materials that matter unites their highly interdisciplinary team of scientists, engineers, designers, and entrepreneurs. Their mission is to reimagine materials at the molecular level and to unleash the potential of biology. They are intrepid, energetic, and purpose-driven.